AMGN AMGEN Inc.

$AMGN demonstrated strong Phase 3 results for TEZSPIRE in eosinophilic esophagitis, with ~68% histologic remission at week 24.

$AMGN: two counts only in Humphreys, negligence and negligence per se. Plaintiffs allege Amgen fell short of HIPAA and FTC Act standards, using them as the care standard, not standalone claims. Nothing to claim. Open Class Actions.

$AMGN so AMGN was at $447 pre-novartis phase 3 fail; now AMGEN has eliminated a competitor, lowered its risk profile and provided a new catalyst!!! AMGN should be at $500!!

Sixty nine percent versus three point five percent is not a close trial, that's a rout. $AMGN and partner $AZN just put full Phase 3 CROSSING numbers on Tezspire in eosinophilic esophagitis, with histologic remission at week 24 hitting 64.8 percent on the 210 mg dose and 68.9 percent on the 420 mg dose against just 3.5 percent on placebo in 368 patients, and the effect held through week 52 while swallowing symptoms kept improving too. That sets up a direct run at Dupixent in a market where it has owned the indication since 2022, with filings now the obvious next step and November 3 earnings as the first place management has to talk size and timing out loud.

$AMGN: being prescribed an Amgen drug alone does not put you in Humphreys. The proposed class centers on people who enrolled in Amgen support, copay or reimbursement programs. No notice list yet, nothing to claim. Open Class Actions.

$AMGN Just sharing: this is gonna change lives and the entire biopharma industry. Check out ICU. Their new device saves half of the people who would otherwise die from sepsis due to cytokine storm. Billions in TAM, about to roll out not just for kids but soon for adults in 2027 and no one realizes the import. 6 Breakthrough Device Designations ranging from Kidney, to Cardio, to Respiratory, cancer patients, infectious diseases... Unreal we can get in on the ground floor. $BMY $SNY $GSK $BIIB

$AMGN oh sheet! Never denied, always delayed. Another 10%+ 🚀 ripper within just days memorialized into the stocktits records. No longer am i doing what I do for Simons’ successor. I am now doing this for Howard. Call me bro. I can help you. $SPY

$AMGN: investors heard about the Amgen breach July 31. Patients may wait longer: SEC disclosure runs in 4 business days, health privacy notice can take up to 60 days. No letters yet, nothing to claim. Open Class Actions.

$AMGN Folks, this is gonna change lives and the entire biopharma industry. Check out ICU. I can't believe the broader market is sleeping on this. Saves half of the people who would otherwise die from sepsis due to cytokine storm. Billions in TAM, about to roll out not just for kids but soon for adults in 2027 and no one realizes the import. 6 Breakthrough Device Designations ranging from Kidney, to Cardio, to Respiratory. Unreal we can get in on the ground floor. $GILD $VRTX $LLY $AZN

$AMGN My last alert long on AMGN was @ 329$ entry alertback in may with 388$ target 1 and open target 2. Since this time I have added back to my position on last week dip below 388$ on a bullish momentum trigger at 380$ (yellow candle print). If 388$ can hold on daily there is now room for the next leg to 540$.

$AMGN UBS upgraded Amgen to Buy on Friday, lifting its target to 470 from 430. That implies about 13% upside from the 414.87 close (per MarketBeat). The street has not caught up to the tape. Consensus is still a Hold, with an average target of 389.71, about 6% below the share price. UBS's 470 is now the high end of the board. Amgen closed Friday up about 2% and is up about 27% this year. The 52-week high is 447.03.

$AMGN up 2.5% after a price-target hike to $380 from $362 at Truist. Amgen stock is now 26% higher on the year and boasts a nearly 40% year-over-year gain the 80-day moving average provided a springboard last month

$AMGN this has had the illest cup and handle break out ive seen in a long time Cant believe i missed it. Huge gap, wonder if it will fill back to the top ?

$AMGN has staged quite the bounce off its 80-day Put skew on the 50-day BTO p/c ratio, too